Biblio

Export 52 results:
Author [ Title(Asc)] Type Year
Filters: Author is Blennow, Kaj  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
E
V. Bloniecki, Aarsland, D., Blennow, K., Cummings, J., Falahati, F., Winblad, B., and Freund-Levi, Y., “Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 57, no. 2, pp. 387-393, 2017.
A. Tofiq, Zetterberg, H., Blennow, K., Basun, H., Cederholm, T., Eriksdotter, M., Faxen-Irving, G., Hjorth, E., Jernerén, F., Schultzberg, M., Wahlund, L. - O., Palmblad, J., and Freund-Levi, Y., “Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimer's Disease: A Randomized Controlled Trial-The OmegAD Study.”, J Alzheimers Dis, vol. 83, no. 3, pp. 1291-1301, 2021.
X. Li, Westman, E., Thordardottir, S., Ståhlbom, A. Kinhult, Almkvist, O., Blennow, K., Wahlund, L. - O., and Graff, C., “The Effects of Gene Mutations on Default Mode Network in Familial Alzheimer's Disease.”, J Alzheimers Dis, vol. 56, no. 1, pp. 327-334, 2017.
J. Toombs, Foiani, M. S., Paterson, R. W., Heslegrave, A., Wray, S., Schott, J. M., Fox, N. C., Lunn, M. P., Blennow, K., and Zetterberg, H., “Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-β Concentration.”, J Alzheimers Dis, vol. 56, no. 3, pp. 885-891, 2017.
Y. Xu, Vasiljevic, E., Deming, Y. K., Jonaitis, E. M., Koscik, R. L., Van Hulle, C. A., Lu, Q., Carboni, M., Kollmorgen, G., Wild, N., Carlsson, C. M., Johnson, S. C., Zetterberg, H., Blennow, K., and Engelman, C. D., “Effect of Pathway-Specific Polygenic Risk Scores for Alzheimer's Disease (AD) on Rate of Change in Cognitive Function and AD-Related Biomarkers Among Asymptomatic Individuals.”, J Alzheimers Dis, vol. 94, no. 4, pp. 1587-1605, 2023.
D
L. Shi, Winchester, L. M., Liu, B. Y., Killick, R., Ribe, E. M., Westwood, S., Baird, A. L., Buckley, N. J., Hong, S., Dobricic, V., Kilpert, F., Franke, A., Kiddle, S., Sattlecker, M., Dobson, R., Cuadrado, A., Hye, A., Ashton, N. J., Morgan, A. R., Bos, I., Vos, S. J. B., Kate, M. Ten, Scheltens, P., Vandenberghe, R., Gabel, S., Meersmans, K., Engelborghs, S., De Roeck, E. E., Sleegers, K., Frisoni, G. B., Blin, O., Richardson, J. C., Bordet, R., Molinuevo, J. L., Rami, L., Wallin, A., Kettunen, P., Tsolaki, M., Verhey, F., Lleo, A., Alcolea, D., Popp, J., Peyratout, G., Martínez-Lage, P., Tainta, M., Johannsen, P., Teunissen, C. E., Freund-Levi, Y., Frölich, L., Legido-Quigley, C., Barkhof, F., Blennow, K., Rasmussen, K. Laura, Nordestgaard, B. Grønne, Frikke-Schmidt, R., Nielsen, S. Fallgaard, Soininen, H., Vellas, B., Kloszewska, I., Mecocci, P., Zetterberg, H., B Morgan, P., Streffer, J., Visser, P. Jelle, Bertram, L., Nevado-Holgado, A. J., and Lovestone, S., “Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 77, no. 3, pp. 1353-1368, 2020.
E. Axelsson Andrén, Kettunen, P., Bjerke, M., Rolstad, S., Zetterberg, H., Blennow, K., Wallin, A., and Svensson, J., “Diagnostic Performance of Cerebrospinal Fluid Neurofilament Light Chain and Soluble Amyloid-β Protein Precursor β in the Subcortical Small Vessel Type of Dementia.”, J Alzheimers Dis, vol. 96, no. 4, pp. 1515-1528, 2023.
C
A. - M. Miller, Balasa, M., Blennow, K., Gardiner, M., Rutkowska, A., Scheltens, P., Teunissen, C. E., Visser, P. Jelle, Winblad, B., Waldemar, G., and Lawlor, B., “Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe.”, J Alzheimers Dis, vol. 60, no. 1, pp. 201-210, 2017.
C. L. Russell, Mitra, V., Hansson, K., Blennow, K., Gobom, J., Zetterberg, H., Hiltunen, M., Ward, M., and Pike, I., “Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates.”, J Alzheimers Dis, vol. 55, no. 1, pp. 303-313, 2017.
N. Lelental, Brandner, S., Kofanova, O., Blennow, K., Zetterberg, H., Andreasson, U., Engelborghs, S., Mroczko, B., Gabryelewicz, T., Teunissen, C., Mollenhauer, B., Parnetti, L., Chiasserini, D., Molinuevo, J. Luis, Perret-Liaudet, A., Verbeek, M. M., Andreasen, N., Brosseron, F., Bahl, J. M. C., Herukka, S. - K., Hausner, L., Frölich, L., Labonte, A., Poirier, J., Miller, A. - M., Zilka, N., Kovacech, B., Urbani, A., Suardi, S., Oliveira, C., Baldeiras, I., Dubois, B., Rot, U., Lehmann, S., Skinningsrud, A., Betsou, F., Wiltfang, J., Gkatzima, O., Winblad, B., Buchfelder, M., Kornhuber, J., and Lewczuk, P., “Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.”, J Alzheimers Dis, vol. 52, no. 1, pp. 51-64, 2016.
A. Morrow, Panyard, D. J., Deming, Y. K., Jonaitis, E., Dong, R., Vasiljevic, E., Betthauser, T. J., Kollmorgen, G., Suridjan, I., Bayfield, A., Van Hulle, C. A., Zetterberg, H., Blennow, K., Carlsson, C. M., Asthana, S., Johnson, S. C., and Engelman, C. D., “Cerebrospinal Fluid Sphingomyelins in Alzheimer's Disease, Neurodegeneration, and Neuroinflammation.”, J Alzheimers Dis, vol. 90, no. 2, pp. 667-680, 2022.
E. van den Berg, Nilsson, J., Kersten, I., Brinkmalm, G., de Kort, A. M., Klijn, C. J. M., Schreuder, F. H. B. M., Jäkel, L., Gobom, J., Portelius, E., Zetterberg, H., Brinkmalm, A., Blennow, K., H Kuiperij, B., and Verbeek, M. M., “Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 467-475, 2023.
S. Lista, Toschi, N., Baldacci, F., Zetterberg, H., Blennow, K., Kilimann, I., Teipel, S. J., Cavedo, E., Santos, A. Melo Dos, Epelbaum, S., Lamari, F., Dubois, B., Nisticò, R., Floris, R., Garaci, F., and Hampel, H., “Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study.”, J Alzheimers Dis, vol. 59, no. 4, pp. 1327-1334, 2017.
K. E. Melah, Lu, S. Yuan- Fu, Hoscheidt, S. M., Alexander, A. L., Adluru, N., Destiche, D. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., Gleason, C. E., N Dowling, M., Bratzke, L. C., Rowley, H. A., Sager, M. A., Asthana, S., Johnson, S. C., and Bendlin, B. B., “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O., “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
M. Bjerke, Kern, S., Blennow, K., Zetterberg, H., Waern, M., Börjesson-Hanson, A., Östling, S., Kern, J., and Skoog, I., “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
S. P. Arnerić, Batrla-Utermann, R., Beckett, L., Bittner, T., Blennow, K., Carter, L., Dean, R., Engelborghs, S., Genius, J., Gordon, M. Forrest, Hitchcock, J., Kaplow, J., Luthman, J., Meibach, R., Raunig, D., Romero, K., Samtani, M. N., Savage, M., Shaw, L., Stephenson, D., Umek, R. M., Vanderstichele, H., Willis, B., and Yule, S., “Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.”, J Alzheimers Dis, vol. 55, no. 1, pp. 19-35, 2017.
C. B. Malpas, Saling, M. M., Velakoulis, D., Desmond, P., Hicks, R. J., Zetterberg, H., Blennow, K., and O'Brien, T. J., “Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type.”, J Alzheimers Dis, vol. 62, no. 1, pp. 417-427, 2018.
P. Lewczuk, Matzen, A., Blennow, K., Parnetti, L., Molinuevo, J. Luis, Eusebi, P., Kornhuber, J., Morris, J. C., and Fagan, A. M., “Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 2, pp. 813-822, 2017.
B. M. Bettcher, Johnson, S. C., Fitch, R., Casaletto, K. B., Heffernan, K. S., Asthana, S., Zetterberg, H., Blennow, K., Carlsson, C. M., Neuhaus, J., Bendlin, B. B., and Kramer, J. H., “Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage.”, J Alzheimers Dis, vol. 62, no. 1, pp. 385-397, 2018.
A
A. M. Racine, Clark, L. R., Berman, S. E., Koscik, R. L., Mueller, K. D., Norton, D., Nicholas, C. R., Blennow, K., Zetterberg, H., Jedynak, B., Bilgel, M., Carlsson, C. M., Christian, B. T., Asthana, S., and Johnson, S. C., “Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 4, pp. 1395-1408, 2016.
P. Chatterjee, Goozee, K., Sohrabi, H. R., Shen, K., Shah, T., Asih, P. R., Dave, P., ManYan, C., Taddei, K., Chung, R., Zetterberg, H., Blennow, K., and Martins, R. N., “Association of Plasma Neurofilament Light Chain with Neocortical Amyloid-β Load and Cognitive Performance in Cognitively Normal Elderly Participants.”, J Alzheimers Dis, vol. 63, no. 2, pp. 479-487, 2018.
M. Edsbagge, Andreasson, U., Ambarki, K., Wikkelsø, C., Eklund, A., Blennow, K., Zetterberg, H., and Tullberg, M., “Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate.”, J Alzheimers Dis, vol. 58, no. 3, pp. 821-828, 2017.
I. Lopez-Font, Boix, C. P., Zetterberg, H., Blennow, K., and Sáez-Valero, J., “Alterations in the Balance of Amyloid-β Protein Precursor Species in the Cerebrospinal Fluid of Alzheimer's Disease Patients.”, J Alzheimers Dis, vol. 57, no. 4, pp. 1281-1291, 2017.
K. E. Osborn, Alverio, J. M., Dumitrescu, L., Pechman, K. R., Gifford, K. A., Hohman, T. J., Blennow, K., Zetterberg, H., and Jefferson, A. L., “Adverse Vascular Risk Relates to Cerebrospinal Fluid Biomarker Evidence of Axonal Injury in the Presence of Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 71, no. 1, pp. 281-290, 2019.

Pages